The IntraLase Method is a 100% blade-free approach to creating your LASIK flap – the thin flap of tissue that the doctor folds back in order to perform your LASIK procedure. The IntraLase Method can only be performed using the IntraLase FS or iFS laser.
Over 5 million procedures have been performed using the IntraLase Method. And, in a clinical survey of LASIK patients who had their corneal flaps created using a microkeratomes in one eye and the IntraLase Method in the other, patients preferred the vision in the IntraLase-treated eye 3:1 over the microkeratomes among those who stated a preference.1
Click Here to Find a Doctor Near You
1. Mahdavi S. IntraLase: Coming of age. Cataract Refract Surg today. October 2005:117-120.
Traditionally, LASIK doctors have used an instrument called a microkeratome for the creation of LASIK flaps. The microkeratome is a hand-held blade that moves across the eye, cutting the LASIK flap as it goes. LASIK is extremely safe, but if complications do occur, the microkeratome is frequently the cause. The IntraLase Method, by contrast, is a 100% blade-free approach to corneal flap creation - enabling your doctor to create an individualized LASIK flap without a blade ever touching your eye.
1. Mahdavi S. IntraLase: Coming of age. Cataract Refract Surg today. October 2005:117-120.
2. Donnenfeld E. Preservation of corneal innervations with femtosecond laser inverted sidecut flaps. Invest Ophthalmol Vis Sci. 2010 51: EAbstract 2855.
3. Durrie DS, Kezirian GM. Femtosecond laser versus mechanical keratome flaps in wavefront-guided laser in-situ keratomileusis: prospective contralateral eye study. J Cataract Refract Surg. 2005;31(1): 120-126.
The creation of the corneal flap prepares the eye for the second step of the LASIK procedure, when another laser, known as an excimer laser, is used to correct vision.
Unlike other procedures, the IntraLase Method creates the corneal flap by applying tiny, rapid pulses of laser light – not a metal blade (microkeratome). Each pulse of light passes through the top layers of your cornea and forms a microscopic bubble at a specific depth and position within your eye that is determined by the doctor. As the IntraLase or iFS Laser moves back and forth across your eye, a uniform layer of bubbles forms just below the corneal surface. Your doctor creates your corneal flap by gently separating the tissue where these bubbles have formed.
Because of the way in which the IntraLase Method creates a precisely positioned layer of bubbles just beneath the surface of your eye, it creates a smooth, even surface after your flap is lifted. The flap is then folded back so the doctor can perform the second step of your LASIK procedure.
The IntraLase Method flap creation process takes less than 15 seconds per eye. Including preparation time, the entire LASIK procedure typically takes about 10 minutes. Once the entire procedure is completed, the corneal flap “locks” back into position.
Leading doctors from around the world believe in the IntraLase Method. Find a trained and certified physician near where you live or work. And to ensure that you get a 100% blade-free LASIK experience, remember to ask for the IntraLase Method by name.
Indications for Use
The IntraLase FS and iFS Lasers are 21 CFR 1040 class IIIb ophthalmic surgical lasers with the following indications for use:
The IntraLase FS and iFS Laser delivery systems are used in conjunction with a sterile disposable IntraLase Patient Interface,
consisting of pre-sterilized suction ring assemblies and pre-sterilized applanation lenses, intended for single-use.
The IntraLase FS and iFS Lasers should only be operated by, or under the direct supervision of a trained physician with certification in
laser safety and in the use of the IntraLase FS Laser.
Flap Contraindications
Lamellar resection for the creation of a corneal flap using the IntraLase FS or iFS Lasers is contraindicated if any of the following
conditions exist. Potential contraindications are not limited to those included in this list:
IntraLase Enabled Keratoplasty (IEK) Contraindications
Contraindications to use of the IntraLase FS or iFS Lasers for the indications described for the IEK procedure include:
The following conditions should also be considered when using the IntraLase FS or iFS Lasers for IEK:
Important Safety Information
Warnings
FS and iFS Lasers
Patient Interface
Flap Complications
Possible complications resulting from Lasik surgery include (potential complications are not limited to those included in this list):
The following sporadically reported visual symptoms may occur following LASIK flap creation with the IntraLase FS or iFS Laser.
Transient Light Sensitivity Syndrome (TLSS)
Transient Light Sensitivity Syndrome is characterized by symptoms of mild to severe light sensitivity which manifests between two and
six weeks postoperatively. Patients experience no decrease in uncorrected or best spectacle-corrected visual acuity. The incidence of
this sensitivity is observed in approximately 1% of patients who undergo flap creation with the IntraLase FS laser. Patients respond to
the use of hourly topical steroids such as Pred Forte, and most report improvement within one week of treatment.
Peripheral Light Spectrum (PLS)
Peripheral Light Spectrum (PLS) is a temporary phenomenon whereby patients report the perception of a spoke-like spectrum of light in
the periphery of their vision. PLS has no clinical examination findings and no effect on visual acuity; however the potential diffractive
effects may be bothersome to some patients. Reported in only 0.03% of cases, the onset of symptoms occurs during the immediate
postoperative period, and typically resolves within three months but may be slightly persistent in rare cases. The visual impact of PLS is
clinically inconsequential for the vast majority of patients.
US Federal law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed eye care
practitioner.quiring initial lamellar resection of the cornea
The IntraLase FS and iFS Laser delivery systems are used in conjunction with a sterile disposable IntraLase Patient Interface,
consisting of pre-sterilized suction ring assemblies and pre-sterilized applanation lenses, intended for single-use.
The IntraLase FS and iFS Lasers should only be operated by, or under the direct supervision of a trained physician with certification in
laser safety and in the use of the IntraLase FS Laser.
Flap Contraindications
Lamellar resection for the creation of a corneal flap using the IntraLase FS or iFS Lasers is contraindicated if any of the following
conditions exist. Potential contraindications are not limited to those included in this list:
IntraLase Enabled Keratoplasty (IEK) Contraindications
Contraindications to use of the IntraLase FS or iFS Lasers for the indications described for the IEK procedure include:
The following conditions should also be considered when using the IntraLase FS or iFS Lasers for IEK:
Important Safety Information
Warnings
FS and iFS Lasers
Patient Interface
Flap Complications
Possible complications resulting from Lasik surgery include (potential complications are not limited to those included in this list):
The following sporadically reported visual symptoms may occur following LASIK flap creation with the IntraLase FS or iFS Laser.
Transient Light Sensitivity Syndrome (TLSS)
Transient Light Sensitivity Syndrome is characterized by symptoms of mild to severe light sensitivity which manifests between two and
six weeks postoperatively. Patients experience no decrease in uncorrected or best spectacle-corrected visual acuity. The incidence of
this sensitivity is observed in approximately 1% of patients who undergo flap creation with the IntraLase FS laser. Patients respond to
the use of hourly topical steroids such as Pred Forte, and most report improvement within one week of treatment.
Peripheral Light Spectrum (PLS)
Peripheral Light Spectrum (PLS) is a temporary phenomenon whereby patients report the perception of a spoke-like spectrum of light in
the periphery of their vision. PLS has no clinical examination findings and no effect on visual acuity; however the potential diffractive
effects may be bothersome to some patients. Reported in only 0.03% of cases, the onset of symptoms occurs during the immediate
postoperative period, and typically resolves within three months but may be slightly persistent in rare cases. The visual impact of PLS is
clinically inconsequential for the vast majority of patients.
US Federal law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed eye care
practitioner.
The IntraLase FS and iFS Laser Systems are ophthalmic surgical lasers indicated for use in patients undergoing surgery or treatment requiring the initial lamellar resection of the cornea, in the creation of a lamellar cut / resection of the cornea for lamellar IntraLase-Enabled Keratoplasty (IEK), in the creation of a penetrating cut/incision for penetrating IEK, penetrating and intrastromal arcuate incisions (iFS Laser Only) and for corneal harvesting. Initial lamellar resection contraindications may include cornea edema, glaucoma, and keratoconus. Initial lamellar resection risks and complications may include corneal pain, flap tearing, and epithelial ingrowth. IEK contraindications may include any corneal opacity adequately dense to obscure visualization of this iris, descemetocoele with impending corneal rupture, previous corneal incisions that might provide a potential space into which the gas produced by the procedure can escape, and cornea thickness requirements that are beyond the range of the system. Patients are requested to consult with their eye care professional for a complete listing of the contraindications and risks. U.S. Federal Law restricts this device to sale, distribution, and use by or on the order of a physician or other licensed eye care professional.
Home | Privacy Policy | Terms of Use | Contact Us
Copyright © 2012 Abbott Laboratories Inc. Abbott Park, Illinois, USA
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company. 2011.12.06-RF4347